Graham Miao - Interpace Diagnostics Insider

Interpace Diagnostics Group Inc -- Exotistan Stock  

USD 0.53  0.06  10.17%

CFO, Executive Vice President Treasurer

Dr. Graham G. Miao Ph.D. is Chief Financial Officer Executive Vice President Treasurer of the Company. effective October 20 2014. Prior to joining PDI Dr. Miao joined us as Executive Vice President Chief Financial Officer and Treasurer in October 2014. Prior to joining PDI Mr. Miao served as Executive Vice President and Chief Financial Officer from September 2011 to September 2014 and held the additional role as interim CoPresident and interim CoChief Executive Officer from September 2013 to September 2014 of Delcath Systems Inc. a NASDAQ traded specialty pharmaceutical and medical device company focused on cancer treatment. From September 2009 until September 2011 Mr. Miao served as Chief of Staff for the Global CFO Organization and as member of the Financial Leadership Team at Dun Bradstreet Corporationrationration a NYSE traded global commercial information services company. Previously Mr. Miao was Executive Vice President CFO of Pagoda Pharmaceuticals a specialty pharmaceuticals and medical device company that was acquired by GlaxoSmithKline. Prior to that Mr. Miao was Vice President of Strategic Planning Financial Analysis at Symrise Inc. a global supplier of flavoring and fragrance products
Age: 49  President Since 2014      
Miao was also Senior Director at ScheringPlough Corporationrationrationration, serving as division CFO for the company?s $3 billion primary care pharmaceuticals franchise. Prior to his time at ScheringPlough, Mr. Miao held senior management positions at Pharmacia Corporationrationrationration, including Director and Head of Finance for the company?s $1.3 billion Global Oncology franchise where he led finance teams across marketing, sales, medical affairs, business development, and mergers & acquisitions. Earlier in his career, Mr. Miao worked as a biotechnology equity analyst at J.P. Morgan and Co and a biomedical researcher at Roche.

Graham Miao Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (15.11) % which means that it has lost $15.11 on every $100 spent on asset. This is way below average.
The company currently holds 27.91 M in liabilities with Debt to Equity (D/E) ratio of 4.76 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Interpace Diagnostics Group Inc has Current Ratio of 1.0 suggesting that it may have difficulties to pay its financial obligations when they are due.

Similar Executives

Found 13 records


MaryonoBank Tabungan Negara
Wayan MertayasaBank Tabungan Negara
Chandra HamzahBank Tabungan Negara
Anthoni SalimIndofood CBP Sukses Makmur Tbk
Andi SetiawanTelekomunikasi Indonesia Perse
AdityawarmanJasa Marga Tbk
Alex SinagaTelekomunikasi Indonesia Perse
Hendri SapariniTelekomunikasi Indonesia Perse
Desi ArryaniJasa Marga Tbk
Refly HarunJasa Marga Tbk
Honesti BasyirTelekomunikasi Indonesia Perse
Ben SantosoIndofood CBP Sukses Makmur Tbk
Benny SantosoIndofood CBP Sukses Makmur Tbk

Entity Summary

PDI, Inc. offer outsourced commercial services to pharmaceutical, biotechnology, diagnostics, and healthcare companies in the United States. Interpace Diagnostics Group Inc (PDII) is traded on Commodity Exchange in Exotistan. It is located in PDI, Inc.Parsippany, NJ and employs 775 people.

Did you try this?

Run Idea Breakdown Now

Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaixs investment ideas are predefined, sector-focused investing themes
Hide  View All  NextLaunch Idea Breakdown
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Interpace Diagnostics Group Inc to your portfolio

Top Management

Interpace Diagnostics Leadership Team
Stephen Sullivan, Director, MBA
Graham Miao, President
Kapila Ratnam, Director
Nancy Lurker, CEO
Jennifer Leonard, SVP
Veronica Lubatkin, Director
Gerald Melillo, Executive
Heiner Dreismann, Director
Jack Stover, Director
Frank Arena, SVP
Asher Dewhurst, Executive
John Federspiel, Director, MBA
Gerald Belle, Chairman, MBA

Stock Performance

Interpace Diagnostics Performance Indicators